JP2016512555A - 急性腎損傷の治療における胎盤幹細胞の使用 - Google Patents

急性腎損傷の治療における胎盤幹細胞の使用 Download PDF

Info

Publication number
JP2016512555A
JP2016512555A JP2016501805A JP2016501805A JP2016512555A JP 2016512555 A JP2016512555 A JP 2016512555A JP 2016501805 A JP2016501805 A JP 2016501805A JP 2016501805 A JP2016501805 A JP 2016501805A JP 2016512555 A JP2016512555 A JP 2016512555A
Authority
JP
Japan
Prior art keywords
stem cells
placental stem
cells
placental
aki
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512555A5 (cg-RX-API-DMAC7.html
Inventor
エー．フィスクコフ スティーブン
エー．フィスクコフ スティーブン
チェン ホング‐ジュング
チェン ホング‐ジュング
Original Assignee
アントフロゲネシス コーポレーション
アントフロゲネシス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントフロゲネシス コーポレーション, アントフロゲネシス コーポレーション filed Critical アントフロゲネシス コーポレーション
Publication of JP2016512555A publication Critical patent/JP2016512555A/ja
Publication of JP2016512555A5 publication Critical patent/JP2016512555A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
JP2016501805A 2013-03-14 2014-03-13 急性腎損傷の治療における胎盤幹細胞の使用 Pending JP2016512555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785252P 2013-03-14 2013-03-14
US61/785,252 2013-03-14
PCT/US2014/025266 WO2014159826A1 (en) 2013-03-14 2014-03-13 Use of placental stem cells in treatment of acute kidney injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018206365A Division JP2019055955A (ja) 2013-03-14 2018-11-01 急性腎損傷の治療における胎盤幹細胞の使用

Publications (2)

Publication Number Publication Date
JP2016512555A true JP2016512555A (ja) 2016-04-28
JP2016512555A5 JP2016512555A5 (cg-RX-API-DMAC7.html) 2017-04-13

Family

ID=51625261

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016501805A Pending JP2016512555A (ja) 2013-03-14 2014-03-13 急性腎損傷の治療における胎盤幹細胞の使用
JP2018206365A Pending JP2019055955A (ja) 2013-03-14 2018-11-01 急性腎損傷の治療における胎盤幹細胞の使用
JP2020180987A Withdrawn JP2021038229A (ja) 2013-03-14 2020-10-29 急性腎損傷の治療における胎盤幹細胞の使用
JP2022176132A Pending JP2023022018A (ja) 2013-03-14 2022-11-02 急性腎損傷の治療における胎盤幹細胞の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018206365A Pending JP2019055955A (ja) 2013-03-14 2018-11-01 急性腎損傷の治療における胎盤幹細胞の使用
JP2020180987A Withdrawn JP2021038229A (ja) 2013-03-14 2020-10-29 急性腎損傷の治療における胎盤幹細胞の使用
JP2022176132A Pending JP2023022018A (ja) 2013-03-14 2022-11-02 急性腎損傷の治療における胎盤幹細胞の使用

Country Status (8)

Country Link
US (2) US20160030488A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968420B1 (cg-RX-API-DMAC7.html)
JP (4) JP2016512555A (cg-RX-API-DMAC7.html)
DK (1) DK2968420T3 (cg-RX-API-DMAC7.html)
ES (1) ES2703784T3 (cg-RX-API-DMAC7.html)
PL (1) PL2968420T3 (cg-RX-API-DMAC7.html)
PT (1) PT2968420T (cg-RX-API-DMAC7.html)
WO (1) WO2014159826A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512970A (ja) * 2016-12-05 2020-04-30 セルラリティ インコーポレイテッド 胎盤接着性細胞を使用するリンパ浮腫および関連する状態の処置

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517402A (ja) * 2002-02-13 2005-06-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物胎盤由来の胚様幹細胞、ならびに該細胞の用途および該細胞を用いる治療法
US20070077201A1 (en) * 2004-09-29 2007-04-05 Reading Christopher L Stem cell expansion and uses
WO2009114826A2 (en) * 2008-03-13 2009-09-17 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases
JP2010518096A (ja) * 2007-02-12 2010-05-27 アンスロジェネシス コーポレーション 胎盤幹細胞を使用した炎症性疾患の治療
JP2010540662A (ja) * 2007-10-05 2010-12-24 エシコン・インコーポレイテッド ヒト臍帯組織由来細胞を用いた腎組織の修復および再建
WO2011127113A1 (en) * 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011127117A1 (en) * 2010-04-07 2011-10-13 Anthrogenesis Corporation Angiogenesis using placental stem cells
WO2013012698A1 (en) * 2011-07-15 2013-01-24 Anthrogenesis Corporation Treatment of radiation injury using amnion derived adherent cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2471903B1 (en) * 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005517402A (ja) * 2002-02-13 2005-06-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物胎盤由来の胚様幹細胞、ならびに該細胞の用途および該細胞を用いる治療法
US20070077201A1 (en) * 2004-09-29 2007-04-05 Reading Christopher L Stem cell expansion and uses
JP2010518096A (ja) * 2007-02-12 2010-05-27 アンスロジェネシス コーポレーション 胎盤幹細胞を使用した炎症性疾患の治療
JP2010540662A (ja) * 2007-10-05 2010-12-24 エシコン・インコーポレイテッド ヒト臍帯組織由来細胞を用いた腎組織の修復および再建
WO2009114826A2 (en) * 2008-03-13 2009-09-17 Angiodynamics, Inc. Treatment systems and methods for renal-related diseases
WO2011127117A1 (en) * 2010-04-07 2011-10-13 Anthrogenesis Corporation Angiogenesis using placental stem cells
WO2011127113A1 (en) * 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2013012698A1 (en) * 2011-07-15 2013-01-24 Anthrogenesis Corporation Treatment of radiation injury using amnion derived adherent cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, vol. 32, no. 7, JPN6017042543, 2009, pages 453, ISSN: 0003829321 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512970A (ja) * 2016-12-05 2020-04-30 セルラリティ インコーポレイテッド 胎盤接着性細胞を使用するリンパ浮腫および関連する状態の処置

Also Published As

Publication number Publication date
US20160030488A1 (en) 2016-02-04
EP2968420B1 (en) 2018-09-05
JP2019055955A (ja) 2019-04-11
US20190388478A1 (en) 2019-12-26
US11696930B2 (en) 2023-07-11
PT2968420T (pt) 2019-01-11
PL2968420T3 (pl) 2019-08-30
DK2968420T3 (da) 2019-01-02
ES2703784T3 (es) 2019-03-12
EP2968420A4 (en) 2016-11-23
JP2021038229A (ja) 2021-03-11
HK1220135A1 (en) 2017-04-28
JP2023022018A (ja) 2023-02-14
EP2968420A1 (en) 2016-01-20
WO2014159826A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
JP6097684B2 (ja) 胎盤幹細胞を用いる血管形成
US20120171161A1 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
KR20230031991A (ko) 단리된 태반 세포를 사용한 뇌졸중 치료
JP2023022018A (ja) 急性腎損傷の治療における胎盤幹細胞の使用
AU2023274138A1 (en) Angiogenesis using stimulated placental stem cells
JP2022184911A (ja) 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療
US20230302058A1 (en) Treatment of lymphedema and related conditions using placental adherent cells
JP2023171769A (ja) 胎盤細胞を使用した糖尿病性末梢神経障害の処置
HK40058728A (en) Treatment of diabetic peripheral neuropathy using placental cells
HK1220135B (en) Use of placental stem cells in treatment of acute kidney injury
AU2017261610A1 (en) Treatment of stroke using isolated placental cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180703